Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Amneal Pharmaceuticals ( (AMRX) ) has issued an announcement.
On July 24, 2025, Amneal Pharmaceuticals announced that its subsidiary priced a $600 million offering of senior secured notes due 2032, reduced from the initially planned $750 million. The company plans to use the proceeds from these notes and a $2.1 billion term loan to refinance existing loans and repay outstanding amounts, with the offering expected to close on August 1, 2025, subject to customary conditions.
The most recent analyst rating on (AMRX) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Amneal Pharmaceuticals stock, see the AMRX Stock Forecast page.
Spark’s Take on AMRX Stock
According to Spark, TipRanks’ AI Analyst, AMRX is a Neutral.
Amneal Pharmaceuticals displays a robust growth trajectory in key segments and strategic initiatives. However, the company’s financial challenges, particularly profitability and high leverage, weigh heavily on the overall stock score. Technical indicators and valuation metrics provide mixed signals, but recent earnings calls and corporate events offer a more positive outlook.
To see Spark’s full report on AMRX stock, click here.
More about Amneal Pharmaceuticals
Amneal Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on the development, manufacturing, and distribution of generic and specialty pharmaceutical products.
Average Trading Volume: 1,765,434
Technical Sentiment Signal: Buy
Current Market Cap: $2.53B
For an in-depth examination of AMRX stock, go to TipRanks’ Overview page.